NCT06706570 2026-03-24
PIK3CA Mutational Status Assessment
European Institute of Oncology
Recruiting
Clinical Trials
13 trialsNCT06750484 2026-02-27
Trial of Trastuzumab Deruxtecan in Previously Treated HER2
Yale University
Phase 2 Recruiting
NCT04059484 2026-02-24
AMEERA-3
Sanofi
Phase 2 Terminated
NCT06849947 2025-12-24
Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer
Samsung Medical Center
Phase 2 Not yet recruiting
NCT04603183 2025-12-12
ABIGAIL
MedSIR
Phase 2 Completed
NCT07076680 2025-11-28
A Real-World Study in Patients With HR+/HER2- Advanced Breast Cancer
SciClone Pharmaceuticals
Withdrawn
NCT04659603 2025-10-01
CARMEN-BT01
Sanofi
Phase 2 Terminated
NCT06616987 2025-08-28
Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer
Samsung Medical Center
Phase 2 Recruiting
NCT06876636 2025-07-29
Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer
Xijing Hospital
Phase NA Active not recruiting
NCT06914661 2025-07-08
EASOFDIMBCT
The First Hospital of Jilin University
Enrolling by invitation
NCT06966141 2025-05-11
A Real World Study of Sacituzumab Govitecan
Fudan University
Recruiting
NCT06945224 2025-04-25
EXPLORE
Fudan University
Active not recruiting
NCT03328884 2025-04-23
Phenomenal
MedSIR
Phase 2 Completed